DrugIn clinical trials

Zolacabtagene autoleucel

zolacabtagene autoleucel

Investigational CD19 CAR-T therapy (Bristol Myers Squibb, BMS-986353) studied in autoimmune diseases. Phase 1 Breakfree-2 multiple sclerosis cohorts (66 patients, MSToronto 2026, interim, single arm): CRS 42.4%, ICANS 7.6%; one fatal septic pneumonia after data cutoff. Not approved.

News about this drug

Also in the catalogue

Scales

Identifiers

INN
zolacabtagene autoleucel

Details

Status
In clinical trials
Class
Autologous CD19-directed CAR-T cell therapy

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.